NICE gives final recomendation to Gazyvaro (obinutuzumab) for CLL- Genentech+ Roche
NICE (The National Institute for Health and Care Excellence) now recommends Gazyvaro (Gazyva in the US) (obinutuzumab) for chronic lymphocytic leukemia (CLL) for previously untreated patients and with co existing medical conditions which are unsuitable for full dose fludarabine based therapy and only if bendamustine therapy is also not suitable.
Comment;.Gazyvaro is the intended successor to Rituxan/MabThera (rituximab)and will eventually compete with rituximab biosmilars when they are introduced in 2017.The NICE decision reverses an earlier decision and came about assisted by revised cost effectiveness data, a discount and the introduction of a patient access scheme .
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins